These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29108718)

  • 1. A new animal model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin.
    Miailhe G; Arfi A; Mirshahi M; Eveno C; Pocard M; Touboul C
    J Visc Surg; 2018 Jun; 155(3):183-189. PubMed ID: 29108718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study.
    Sánchez-García S; Villarejo-Campos P; Padilla-Valverde D; Amo-Salas M; Martín-Fernández J
    Int J Hyperthermia; 2016 Aug; 32(5):488-95. PubMed ID: 27056558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
    Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
    BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
    Bakrin N; Bereder JM; Decullier E; Classe JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Morice P; Pomel C; Pocard M; Guyon F; Porcheron J; Glehen O;
    Eur J Surg Oncol; 2013 Dec; 39(12):1435-43. PubMed ID: 24209430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
    Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
    Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.
    Frenel JS; Leux C; Pouplin L; Ferron G; Berton Rigaud D; Bourbouloux E; Dravet F; Jaffre I; Classe JM
    J Surg Oncol; 2011 Jan; 103(1):10-6. PubMed ID: 21031424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
    J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
    Delhorme JB; Triki E; Romain B; Meyer N; Rohr S; Brigand C
    J Visc Surg; 2015 Jun; 152(3):149-54. PubMed ID: 25650364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
    Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
    J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
    Elias D; Pocard M; Goere D
    Cancer Treat Res; 2007; 134():303-18. PubMed ID: 17633062
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Perfusate Concentration on Hyperthermic Intraperitoneal Chemotherapy Efficacy and Toxicity in a Rodent Model.
    Liesenfeld LF; Hillebrecht HC; Klose J; Schmidt T; Schneider M
    J Surg Res; 2020 Sep; 253():262-271. PubMed ID: 32388389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
    Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
    Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
    Leung V; Huo YR; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
    Golse N; Bakrin N; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O; Cotte E
    J Surg Oncol; 2012 Aug; 106(2):197-203. PubMed ID: 22331814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
    Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.